MindMaze Therapeutics Holding SA
MindMaze Therapeutics Holding SA is a Switzerland-based life sciences company specializing in precision neurology and brain health through an AI-enabled neurotechnology platform. Formed via the business combination of NeuroX Group and Relief Therapeutics, it integrates biopharmaceutical development for rare and specialty diseases with digital therapeutics, motion analytics, and proprietary devices to deliver motor and cognitive rehabilitation. Key products include MindPod, an immersive platform for brain recovery; MindMotion GO, a neurorehabilitation system for clinical and home use; Izar, a hand training peripheral for conditions like stroke and Parkinson’s; and Physilog, for 3D motion assessments and digital biomarkers. The company advances drug candidates using proprietary delivery technologies like Physiomimic and TEHCLOTM, targeting rare metabolic and dermatological diseases. With over 35,000 patients treated, multiple regulatory approvals, and a unique US CAT-3 reimbursement code, MindMaze Therapeutics Holding SA bridges biopharma and digital health, supporting care across the continuum from acute settings to home, while fostering partnerships with pharma and providers to address unmet needs in neurology.
$0.20
+$0.00 (+0.00%)
Price from 2 days ago
The business is unprofitable at the operating level (-93.93% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 39.5% YoY with margins expanding 233.9pp.
Negative free cash flow of -CHF 3M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
CHF 8M
▲ +39.5% YoY
Net Income (TTM)
-CHF 17M
▲ +82.6% YoY
Op. Margin
-93.93%
▲ +233.9pp YoY
ROIC
-13.29%
▲ +2.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-CHF 3M
▲ +82.9% YoY
Op. Cash Flow (TTM)
-CHF 3M
▲ +83.4% YoY
Net Debt
-CHF 13M
Net Cash Position
Cash & Equiv.
CHF 15M
3Y CAGR: +36.3%
Continue Research
Is MindMaze Therapeutics Holding SA (RLFTF) overvalued?
MindMaze Therapeutics Holding SA (RLFTF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, MindMaze Therapeutics Holding SA scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is MindMaze Therapeutics Holding SA a high-quality business?+
MindMaze Therapeutics Holding SA scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -93.9% operating margin and a -13.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is MindMaze Therapeutics Holding SA a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh RLFTF's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.